Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis.
Rheumatoid arthritis (RA) is a prevalent and debilitating autoimmune disease that affects the joints. RA is characterized by an infiltration of the affected joint by blood-derived cells. In response to activation, these cells generate reactive oxygen species, resulting in an oxidative stress situation. One approach to counteract this oxidative stress situation is the use of antioxidants as therapeutic agents. The free radical scavenger enzyme superoxide dismutase (SOD) may be used as a therapeutic agent in rheumatoid arthritis, but its rapid elimination from the circulation is a major limitation. Targeted delivery of SOD may overcome this limitation. In this study, the utility of PEGylated liposomes (PEG-liposomes) for targeting SOD to arthritic sites was explored. The targeting of SOD to arthritic sites following intravenous administration of both PEG-liposomes and positively charged liposomes lacking PEG but containing stearylamine (SA-liposomes) in rats with adjuvant arthritis was studied. At 24 h post injection, the blood levels of long circulating liposomes with a mean size of 0.11 micrometer and 0.20 micrometer were 8- and 3-fold higher, respectively, as compared to the SA-liposomes. The majority of SOD administered in liposomal form remains within the liposomes when they circulate in the bloodstream. The highest target uptake was observed with PEG-liposomes with a mean size of 0.11 micrometer and the lowest uptake with the SA-liposomes. These results demonstrate that SOD can be targeted to inflamed sites most efficiently via small-sized PEG-liposomes. Small-sized PEG-coated liposomes are to be preferred if prolonged circulation and enhanced localization of SOD at arthritic sites are desired.
Unidade de Novas Formas de Agentes Bioactivos - DB - IBQTA - INETI, Estrada do Paço do Lumiar, 1649-038, Lisbon, Portugal. luisa.corvo@ibqta.ineti.pt
M L
ML
Corvo
O C
OC
Boerman
W J
WJ
Oyen
L
L
Van Bloois
M E
ME
Cruz
D J
DJ
Crommelin
G
G
Storm
D000818:Animals; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D004195:Disease Models, Animal; D004337:Drug Carriers; D005528:Foot / Q000000981:diagnostic imaging; D006321:Heart / Q000000981:diagnostic imaging; D007205:Indium Radioisotopes; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D008081:Liposomes / Q000493:pharmacokinetics; D008297:Male; D009161:Mycobacterium; D010316:Particle Size; D004369:Pentetic Acid; D010714:Phosphatidylethanolamines; D011092:Polyethylene Glycols; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013997:Time Factors; D014018:Tissue Distribution
D004337:Drug Carriers; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D008081:Liposomes; D010714:Phosphatidylethanolamines; C107570:polyethylene glycol-distearoylphosphatidylethanolamine; D011092:Polyethylene Glycols; D004369:Pentetic Acid; D013482:Superoxide Dismutase